Mga Batayang Estadistika
| LEI | 529900ONJHY8EOGYT555 |
| CIK | 1439222 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Agios Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 31, 2025 |
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Agios Reports Second Quarter 2025 Financial Results and Provides Business Update •$12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securities •PYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal date of September 7, 2025 •Topline results from RISE UP Phase 3 tr |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, INC |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 31, 2025 |
greement, dated June 5, 2025, between the Registrant and GNS Healthcare, Inc. d/b/a Aitia Exhibit 10.2 SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (the “Sublease”) is made as of the 5th day of June, 2025, by and between Agios Pharmaceuticals, Inc., a Delaware corporation (“Sublandlord”) and GNS Healthcare, Inc. d/b/a Aitia, a Delaware corporation (“Subtenant”). RECITALS: WHEREAS, BRE-BMR 64 SIDNEY LLC, a Delaware limited liability company (“Landlord”), successor in interest to Up 64 Sid |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 18, 2025 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Agios Pharmaceuticals, Inc. |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 18, 2025 |
2023 Stock Incentive Plan, as amended EX-99.1 Exhibit 99.1 AGIOS PHARMACEUTICALS, INC. 2023 STOCK INCENTIVE PLAN, AS AMENDED 1. Purpose The purpose of this 2023 Stock Incentive Plan (the “Plan”) of Agios Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important con |
|
| June 18, 2025 |
As filed with the Securities and Exchange Commission on June 18, 2025 S-8 As filed with the Securities and Exchange Commission on June 18, 2025 Registration No. |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 1, 2025 |
Exhibit 99.1 Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights – U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Teb |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, IN |
|
| April 25, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| April 25, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| March 5, 2025 |
Form of Inducement Restricted Stock Unit Agreement Exhibit 99.2 AGIOS PHARMACEUTICALS, INC. Inducement Restricted Stock Unit Agreement (Time-Vested) Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) NOTICE OF GRANT This Inducement Restricted Stock Unit Agreement (this “Agreement”) is made as of the Agreement Date between Agios Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and the Participant. I. Agreement Date Date: |
|
| March 5, 2025 |
Form of Inducement Stock Option Agreement Exhibit 99.1 AGIOS PHARMACEUTICALS, INC. Inducement Nonstatutory Stock Option Award Agreement 1. Grant of Option. This agreement (the “Award Agreement”) evidences the inducement nonstatutory stock option granted by Agios Pharmaceuticals, Inc., a Delaware corporation (the “Company”), on [], 2025 (the “Grant Date”) to Krishnan Viswanadhan (the “Participant”), of an option to purchase, in whole or in |
|
| March 5, 2025 |
Form of Inducement Performance Stock Unit Agreement Exhibit 99.3 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AGIOS PHARMACEUTICALS, INC. Inducement Performance Stock Unit Agreement Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) NOTICE OF GRANT This I |
|
| March 5, 2025 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Agios Pharmaceuticals, Inc. |
|
| March 5, 2025 |
As filed with the Securities and Exchange Commission on March 5, 2025 As filed with the Securities and Exchange Commission on March 5, 2025 Registration No. |
|
| February 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 13, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Entity State or other Jurisdiction of Incorporation or Organization Agios Securities Corporation Massachusetts Agios Limited Bermuda Agios International Sarl (GmbH) Switzerland Agios Netherlands B.V. The Netherlands Agios Germany GmbH Germany Agios Italy S.R.L. Italy Agios France SARL France |
|
| February 13, 2025 |
Exhibit 99.1 Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights – Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 – |
|
| February 13, 2025 |
Ex. 19.1 Agios Pharmaceuticals, Inc. Insider Trading Policy Adopted by the Board of Directors on March 2, 2023 Effective March 3, 2023 1.Background and Purpose 1.1Why Have We Adopted This Policy? The federal securities laws prohibit any member of the Board of Directors (a “Director”), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), a |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, INC. (E |
|
| February 13, 2025 |
Amended and Restated 2013 Employee Stock Purchase Plan Ex. 10.4 AGIOS PHARMACEUTICALS, INC. AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN Amended and Restated on December 2, 2024 The purpose of this Plan is to provide eligible employees of Agios Pharmaceuticals, Inc. (the “Company”) and certain of its subsidiaries with opportunities to purchase shares of the Company’s common stock, $0.001 par value (the “Common Stock”), commencing at such tim |
|
| February 4, 2025 |
EX-2 3 poa.htm POWER OF ATTORNEY FOR PATRICK (CHENG) LUO EXHIBIT 2 POWER OF ATTORNEY The undersigned hereby appoints each of Hannah E. Dunn, Philip D. Dreyfuss, David T. Kim, Thomas G. Roberts, Jr., John R. Warren, and Mark C. Wehrly his or her true and lawful attorney-in-fact and agent to execute and file with the Securities and Exchange Commission any Schedule 13D, Schedule 13G, any amendments t |
|
| February 4, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EX-1 2 jas.htm JOINT ACQUISITION STATEMENT EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addi |
|
| January 13, 2025 |
Exhibit 99.1 Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio – FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia; PDUFA Goal Date is September 7, 2025 – – Topline Results from Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease to be An |
|
| January 13, 2025 |
J.P. Morgan Healthcare Conference Agios Pharmaceuticals Brian Goff, Chief Executive Officer January 15, 2025 Exhibit 99.2 Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2025 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2024 |
AGIO / Agios Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-agio093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 00847X104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| November 8, 2024 |
AGIO / Agios Pharmaceuticals, Inc. / Farallon Capital Partners, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS |
|
| October 31, 2024 |
Exhibit 99.1 Agios Reports Business Highlights and Third Quarter 2024 Financial Results – Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma and Servier, Following FDA Approval of Vorasidenib – – Commenced Enrollment of the Phase 2b Study of Tebapivat |
|
| October 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 1, 2024 |
Exhibit 99.1 Agios Reports Business Highlights and Second Quarter 2024 Financial Results – Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 – – Announced $905 Million Purchase Agreement for Vorasidenib Royalty with Royalty Pharma; Agios to Receive a Total of $1.1 Billion i |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, INC |
|
| August 1, 2024 |
Exhibit 10.1 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. PURCHASE AND SALE AGREEMENT dated as of May 24, 2024 by and between AGIOS PHARMACEUTICALS, INC., as SELLER and ROYALTY PHARMA INVESTMENTS 201 |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 11, 2024 |
June 11, 2024 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Sasha Parikh Tracie Mariner Re: AGIOS PHARMACEUTICALS, INC. Form 10-K for Fiscal Year Ended December 31, 2023 Filed February 15, 2024 File No. 001-36014 Ladies and Gentlemen: This letter is in response to the letter (the “Letter”) dated Ma |
|
| May 28, 2024 |
Exhibit 99.1 Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty – Royalty Pharma to Acquire Rights to Agios’ 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905 Million Upfront upon FDA Approval of Vorasidenib; Agios to Share in Economics Above Certain Revenue Thresholds – – Agios Retains Rights to $200 Million Milestone Payment from Servier upon FDA Approval of Voras |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 2, 2024 |
Exhibit 99.1 Agios Reports Business Highlights and First Quarter 2024 Financial Results – Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 – – Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia in January |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, IN |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| February 15, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Entity State or other Jurisdiction of Incorporation or Organization Agios Securities Corporation Massachusetts Agios Limited Bermuda Agios International Sarl (GmbH) Switzerland Agios Netherlands B.V. The Netherlands Agios Germany GmbH Germany Agios Italy S.R.L. Italy Agios France SARL France |
|
| February 15, 2024 |
Dodd-Frank Compensation Recovery Policy Ex. 97.1 AGIOS PHARMACEUTICALS, INC. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Agios Pharmaceuticals, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Dodd-F |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, INC. (E |
|
| February 15, 2024 |
Sublease Agreement, dated April 14, 2023, between the Registrant and Watershed Informatics, Inc. Ex. 10.21 SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (the “Sublease”) is made as of the 14th day of April, 2023, by and between Agios Pharmaceuticals, Inc., a Delaware corporation (“Sublandlord”) and Watershed Informatics, Inc., a Delaware corporation (“Subtenant”). RECITALS: WHEREAS, BRE-BMR 64 SIDNEY LLC, a Delaware limited liability company (“Landlord”), successor in interest to Up 64 Sidney St |
|
| February 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 15, 2024 |
Exhibit 99.1 Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights – Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia – – Presented Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition – |
|
| February 14, 2024 |
AGIO / Agios Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
AGIO / Agios Pharmaceuticals, Inc. / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
AGIO / Agios Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d687782dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to |
|
| February 12, 2024 |
AGIO / Agios Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Agios Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 00847X104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 12, 2024 |
AGIO / Agios Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0012-agiospharmaceuticalsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Agios Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 00847X104 Date of Event Which Requires Filing of this Statement: January 31, 2024 Check the appropriate box t |
|
| February 8, 2024 |
AGIO / Agios Pharmaceuticals, Inc. / Farallon Capital Partners, L.P. Passive Investment SC 13G/A 1 agio13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Agios Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00847X104 (Cusip Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appro |
|
| January 8, 2024 |
EX-99.2 J.P. Morgan Healthcare Conference Agios Pharmaceuticals Brian Goff, Chief Executive Officer January 10, 2024 Exhibit 99.2 Forward-looking statements This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the p |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 8, 2024 |
EX-99.1 Exhibit 99.1 Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio – Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data in Non-Transfusion-Dependent Thalassemia – – Company Expects Four Additional Phase 3 Readouts by the End of 2025, with Potential FDA Approvals in Thalassemi |
|
| November 9, 2023 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11 )* Agios Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) October 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| November 9, 2023 |
AGIO / Agios Pharmaceuticals Inc / Farallon Capital Partners, L.P. Passive Investment SC 13G 1 agio13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Agios Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00847X104 (Cusip Number) October 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| November 2, 2023 |
Exhibit 99.1 Agios Reports Business Highlights and Third Quarter 2023 Financial Results – First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease – – Completed Enrollment in Phase 3 ACTIVATE-KidsT Pediatric Study of Mitapivat in PK Deficiency; ACTIVATE-Kids Study Achieves >50% Enrollment – – On Track for Data Readouts in Two Phase 3 Trials of Mitapiv |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| August 3, 2023 |
Form of Restricted Stock Unit Agreement Under 2023 Stock Incentive Plan AGIOS PHARMACEUTICALS, INC. Restricted Stock Unit Agreement Agios Pharmaceuticals, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2023 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of restricted stock units (“RSUs”) granted: Vesting Start Date: |
|
| August 3, 2023 |
Exhibit 99.1 Agios Reports Business Highlights and Second Quarter 2023 Financial Results –Announced Positive Results from Phase 2 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease; On Track to Enroll First Patient in Phase 3 Portion of the Study in Q4 2023 –Completed Enrollment in Phase 3 ENERGIZE and ENERGIZE-T Studies of Mitapivat in Thalassemia and Phase 2a Study of AG-94 |
|
| August 3, 2023 |
Form of Restricted Stock Unit Agreement (Performance-Based) Under 2023 Stock Incentive Plan AGIOS PHARMACEUTICALS, INC. Restricted Stock Unit Agreement (Performance-Based) Agios Pharmaceuticals, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2023 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of restricted stock units (“RSUs”) granted: |
|
| August 3, 2023 |
Form of Stock Option Agreement Under 2023 Stock Incentive Plan AGIOS PHARMACEUTICALS, INC. Stock Option Agreement Agios Pharmaceutical, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2023 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Incentive Stock Option or Nonstatutory Stock Option: Number of shares of the Company’s Comm |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 13, 2023 |
EX-99.1 Exhibit 99.1 AGIOS PHARMACEUTICALS, INC. 2023 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2023 Stock Incentive Plan (the “Plan”) of Agios Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions t |
|
| June 13, 2023 |
As filed with the Securities and Exchange Commission on June 13, 2023 S-8 1 d482039ds8.htm S-8 As filed with the Securities and Exchange Commission on June 13, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-0662915 (State or Other Jurisdiction of Incorporati |
|
| June 13, 2023 |
Calculation of Filing Fee Tables EX-FILING FEES 5 d482039dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Ra |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 4, 2023 |
Separation Agreement, dated December 16, 2022, by and between the Registrant and Richa Poddar December 16, 2022 Richa Poddar 32 Anderson Street #1 Boston, MA 02114 RE: Confidential Separation Agreement and General Release Dear Richa: This Confidential Separation Agreement and General Release (the “Agreement”) sets forth and confirms the understanding between you and Agios Pharmaceuticals, Inc. |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 4, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| May 4, 2023 |
Exhibit 99.1 Agios Reports Business Highlights and First Quarter 2023 Financial Results •On Track for PYRUKYND® (mitapivat) Data Readouts of the Phase 2 Portion of the RISE UP Study in Sickle Cell Disease in Mid-2023 and the Phase 3 ENERGIZE and ENERGIZE-T Studies in Thalassemia in 2024 •U.S. PYRUKYND® Net Revenue of $5.6 Million in Q1; $1.0 Billion of Cash, Cash Equivalents and Marketable Securit |
|
| April 26, 2023 |
DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10 )* Agios Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) March 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 3, 2023 |
Third Amended and Restated By-Laws EX-3.1 Exhibit 3.1 THIRD AMENDED AND RESTATED BY-LAWS OF AGIOS PHARMACEUTICALS, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Nomination of Directors 3 1.11 Notice of Business at Annual Meetings 7 |
|
| February 23, 2023 |
As filed with the Securities and Exchange Commission on February 23, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
Purchase and Sale Agreement, dated October 27, 2022, by and among the Registrant, Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| February 23, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Entity State or other Jurisdiction of Incorporation or Organization Agios Securities Corporation Massachusetts Agios Limited Bermuda Agios International Sarl (GmbH) Switzerland Agios Netherlands B.V. The Netherlands Agios Germany GmbH Germany Agios Italy S.R.L. Italy Agios France SARL France |
|
| February 23, 2023 |
Consulting Agreement, dated January 1, 2023, by and between the Registrant and Richa Poddar CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (together with the attached Business Terms Exhibit, the “Agreement”), is entered into as of January 1, 2023 (the “Effective Date”) by and between Agios Pharmaceuticals, Inc. |
|
| February 23, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| February 23, 2023 |
Form of Subordinated Indenture EX-4.5 Exhibit 4.5 AGIOS PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.086.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.014.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4 |
|
| February 23, 2023 |
EX-4.7 Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER N |
|
| February 23, 2023 |
EX-4.4 Exhibit 4.4 AGIOS PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 3 |
|
| February 23, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Agios Pharmaceuticals, Inc. |
|
| February 23, 2023 |
As filed with the Securities and Exchange Commission on February 23, 2023 S-8 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
Letter Agreement, dated as of December 5, 2022, between the Registrant and Tsveta Milanova EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made as of December 5, 2022 by and between Agios Pharmaceuticals, Inc. |
|
| February 23, 2023 |
Exhibit 99.1 Agios Reports Fourth Quarter and Full Year 2022 Financial Results – Completed Enrollment in Phase 2 RISE UP Study of PYRUKYND® (mitapivat)in Sickle Cell Disease – – On Track to Complete Enrollment in Phase 3 ENERGIZE and ENERGIZE-T Studies of PYRUKYND in Thalassemia by Mid-2023 – – U.S. PYRUKYND® Launch Provides Capability Building Platform to Support Expected Future Product Growth an |
|
| February 23, 2023 |
EX-4.6 Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| February 23, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Agios Pharmaceuticals, Inc. |
|
| February 23, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 14, 2023 |
AGIO / Agios Pharmaceuticals Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d398218dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to d |
|
| February 14, 2023 |
AGIO / Agios Pharmaceuticals Inc / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
AGIO / Agios Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
EX-99.B 2 d398218dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 9, 2023 |
AGIO / Agios Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Agios Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 00847X104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9 )* Agios Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 9, 2023 |
EX-99.2 3 d408672dex992.htm EX-99.2 Fueled by Connections to Transform Rare Diseases Brian Goff, Chief Executive Officer January 11, 2023 Exhibit 99.2 Forward-looking statements This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include |
|
| January 9, 2023 |
EX-99.1 2 d408672dex991.htm EX-99.1 Exhibit 99.1 Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases – Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase (PK) deficiency – – Driving toward two additional P |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 3, 2023 |
As filed with the Securities and Exchange Commission on January 3, 2023 S-8 1 d398924ds8.htm S-8 As filed with the Securities and Exchange Commission on January 3, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-0662915 (State or Other Jurisdiction of Incorpora |
|
| January 3, 2023 |
Form of Inducement Performance Stock Unit Agreement for Tsveta Milanova EX-99.3 6 d398924dex993.htm EX-99.3 Exhibit 99.3 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AGIOS PHARMACEUTICALS, INC. Inducement Performance Stock Unit Agreement Inducement Grant Pursuant to Nasdaq Stock Market Ru |
|
| January 3, 2023 |
Form of Inducement Restricted Stock Unit Agreement for Tsveta Milanova Exhibit 99.2 AGIOS PHARMACEUTICALS, INC. Inducement Restricted Stock Unit Agreement (Time-Vested) Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) NOTICE OF GRANT This Inducement Restricted Stock Unit Agreement (this ?Agreement?) is made as of the Agreement Date between Agios Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, and the Participant. I. Agreement Date Date: |
|
| January 3, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Agios Pharmaceuticals, Inc. |
|
| January 3, 2023 |
Form of Inducement Stock Option Agreement for Tsveta Milanova Exhibit 99.1 AGIOS PHARMACEUTICALS, INC. Inducement Nonstatutory Stock Option Award Agreement 1. Grant of Option. This agreement (the ?Award Agreement?) evidences the inducement nonstatutory stock option granted by Agios Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), on [], 2023 (the ?Grant Date?) to Tsveta Milanova (the ?Participant?), of an option to purchase, in whole or in part |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 (December 12, 2022) Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Inco |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 (December 5, 2022) Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorp |
|
| December 6, 2022 |
Agios Appoints Tsveta Milanova as Chief Commercial Officer EX-99.1 Exhibit 99.1 Agios Appoints Tsveta Milanova as Chief Commercial Officer CAMBRIDGE, Mass., December 6, 2022 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the appointment of Tsveta Milanova to the role of chief commercial officer, effective Jan. 3, 2023. Ms. Milanova will succeed Richa Poddar |
|
| November 3, 2022 |
Exhibit 99.1 Agios Reports Business Highlights and Third Quarter 2022 Financial Results ? U.S. PYRUKYND? (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion; Net Revenue of $3.5 Million in Q3 ? ? Received Positive CHMP Opinion for PYRUKYND? in Adults with Pyruvate Kinase (PK) Deficiency ? ? On Track to Meet Year-end Enrollment Targets in |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 3, 2022 |
Letter Agreement, dated as of September 16, 2022, between the Registrant and Cecilia Jones Exhibit 10.5 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made as of September 15, 2022 by and between Agios Pharmaceuticals, Inc. (the ?Company?), and M. Cecilia Jones (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS the Company desires to employ the Executive as its Chief Financial Officer; and WHEREAS, the Executive has agreed to accept such employment on the |
|
| October 27, 2022 |
Exhibit 99.1 Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO? Royalty ? Sagard Healthcare Partners Acquires Rights to Agios? 5% Royalty on TIBSOVO? U.S. Net Sales ? CAMBRIDGE, Mass. and TORONTO, October 27, 2022 ? Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined |
|
| October 27, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 7, 2022 |
Amended and Restated Severance Benefits Plan EX-10.1 2 d363139dex101.htm EX-10.1 Exhibit 10.1 AGIOS PHARMACEUTICALS, INC. Amended and Restated Severance Benefits Plan Effective October 6, 2022 1. Establishment of Plan. Agios Pharmaceuticals, Inc., a Delaware corporation (the “Company”), originally established this plan effective April 22, 2016, and has amended and restated this plan effective as of the date set forth above, as an unfunded se |
|
| October 6, 2022 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 00847X104 (CUSIP Number) September 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| September 26, 2022 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Agios Pharmaceuticals, Inc. |
|
| September 26, 2022 |
Form of Inducement Performance Stock Unit Agreement for Cecilia Jones Exhibit 99.3 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AGIOS PHARMACEUTICALS, INC. Inducement Performance Stock Unit Agreement Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) NOTICE OF GRANT This I |
|
| September 26, 2022 |
Form of Inducement Stock Option Agreement for Cecilia Jones Exhibit 99.1 AGIOS PHARMACEUTICALS, INC. Inducement Nonstatutory Stock Option Award Agreement 1. Grant of Option. This agreement (the ?Award Agreement?) evidences the inducement nonstatutory stock option granted by Agios Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), on [], 2022 (the ?Grant Date?) to M. Cecilia Jones (the ?Participant?), of an option to purchase, in whole or in par |
|
| September 26, 2022 |
Power of attorney (included on the signature pages of this registration statement) As filed with the Securities and Exchange Commission on September 26, 2022 Registration No. |
|
| September 26, 2022 |
Form of Inducement Restricted Stock Unit Agreement for Cecilia Jones Exhibit 99.2 AGIOS PHARMACEUTICALS, INC. Inducement Restricted Stock Unit Agreement (Time-Vested) Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) NOTICE OF GRANT This Inducement Restricted Stock Unit Agreement (this ?Agreement?) is made as of the Agreement Date between Agios Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, and the Participant. I. Agreement Date Date: |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 19, 2022 |
Agios Appoints Cecilia Jones as Chief Financial Officer Exhibit 99.1 Agios Appoints Cecilia Jones as Chief Financial Officer CAMBRIDGE, Mass., September 19, 2022 ? Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined diseases, today announced the appointment of Cecilia Jones to the role of chief financial officer, effective Sept. 26, 2022. Ms. Jones will replace J |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 8, 2022 |
Calculation of Filing Fee Tables EX-FILING FEES 4 d379562dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Ra |
|
| August 8, 2022 |
As filed with the Securities and Exchange Commission on August 8, 2022 As filed with the Securities and Exchange Commission on August 8, 2022 Registration No. |
|
| August 4, 2022 |
Form of Inducement Stock Option Agreement for Brian Goff Exhibit 10.3 AGIOS PHARMACEUTICALS, INC. Inducement Nonstatutory Stock Option Award Agreement 1. Grant of Option. This agreement (the ?Award Agreement?) evidences the inducement nonstatutory stock option granted by Agios Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), on [], 2022 (the ?Grant Date?) to Brian Goff (the ?Participant?), of an option to purchase, in whole or in part, on |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| August 4, 2022 |
Form of Inducement Restricted Stock Unit Agreement for Brian Goff Exhibit 10.4 AGIOS PHARMACEUTICALS, INC. Inducement Restricted Stock Unit Agreement (Time-Vested) Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) NOTICE OF GRANT This Inducement Restricted Stock Unit Agreement (this ?Agreement?) is made as of the Agreement Date between Agios Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, and the Participant. 1.Agreement Date Date: |
|
| August 4, 2022 |
Exhibit 99.1 Agios Reports Business Highlights and Second Quarter 2022 Financial Results ? Generated $3.1 Million in Net U.S. Revenue for First Full Quarter of PYRUKYND? (mitapivat) Sales ? ? Brian Goff to Become Chief Executive Officer at Agios on August 8, 2022, Leveraging 30+ Years of Biopharma Experience, Including Significant Expertise in Rare Disease and Hematology; Current CEO Jackie Fouse |
|
| August 4, 2022 |
Form of Inducement Performance Stock Unit Agreement for Brian Goff Exhibit 10.5 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AGIOS PHARMACEUTICALS, INC. Inducement Performance Stock Unit Agreement Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4) NOTICE OF GRANT This I |
|
| August 4, 2022 |
Letter Agreement, dated July 8, 2022, between the Registrant and Brian Goff Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made as of July 8, 2022 by and between Agios Pharmaceuticals, Inc. (the ?Company?), and Brian Goff (the ?Executive?) (together, the ?Parties?). RECITALS WHEREAS the Company desires to employ the Executive as its Chief Executive Officer; and WHEREAS, the Executive has agreed to accept such employment on the terms and c |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 4, 2022 |
Consulting Agreement, dated May 23, 2022, by and between the Company and Bruce Car Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (together with the attached Business Terms Exhibit, the ?Agreement?), is entered into as of August 1, 2022 (the ?Effective Date?) by and between Agios Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 88 Sidney Street, Cambridge, MA 02139 (?Agios?) and Bruce Car, an individual with a main address at 135 U |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 12, 2022 |
Exhibit 99.1 Agios Appoints Brian Goff as Chief Executive Officer ? Current CEO, Jackie Fouse, Ph.D., to Transition to Chair of Board of Directors Effective August 8, 2022 ? ? Agios to Host Investor Webcast Today at 4:30pm ET ? CAMBRIDGE, Mass., July 12, 2022 ? Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined dise |
|
| June 22, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 5, 2022 |
Exhibit 99.1 Agios Reports Business Highlights and First Quarter 2022 Financial Results ? Received U.S. FDA Approval for PYRUKYND?, the First Therapy for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) deficiency and Agios? First Genetically Defined Disease Medicine, U.S. Launch Underway ? ? PYRUKYND? Pivotal Studies in Thalassemia and Sickle Cell Disease Open and Enrolling; |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 28, 2022 |
DEF 14A 1 d288567ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 S-8 1 d238795ds8.htm S-8 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-0662915 (State or Other Jurisdiction of Incorpo |
|
| February 24, 2022 |
SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (the ?Sublease?) is made as of the 27th day of July, 2021, by and between Agios Pharmaceuticals, Inc. |
|
| February 24, 2022 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Agios Pharmaceuticals, Inc. |
|
| February 24, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Entity State or other Jurisdiction of Incorporation or Organization Agios Securities Corporation Massachusetts Agios Limited Bermuda Agios International Sarl (GmbH) Switzerland Agios Netherlands B.V. The Netherlands Agios Germany GmbH Germany Agios Italy S.R.L. Italy Agios France SARL France |
|
| February 24, 2022 |
Exhibit 99.1 Agios Reports Fourth Quarter and Full Year 2021 Financial Results ? Received FDA Approval of PYRUKYND? (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder ? ? First Patients Dosed in All Three Pivotal Trials of PYRUKYND? in Thalassemia and Sickle Cell Disease ? ? Cash, Cash Equivalents an |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 11, 2022 |
AGIO / Agios Pharmaceuticals Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 9, 2022 |
AGIO / Agios Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0177-agiospharmaceuticalsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Agios Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 00847X104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* Agios Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 19, 2022 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 per share (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2022 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 9, 2021 |
AGIO / Agios Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Agios Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 00847X104 Date of Event Which Requires Filing of this Statement: November 30, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 3, 2021 |
SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (the ?Sublease?) is made as of the 27th day of July, 2021, by and between Agios Pharmaceuticals, Inc. |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| November 3, 2021 |
Exhibit 99.1 Agios Reports Business Highlights and Third Quarter 2021 Financial Results ? Received FDA Priority Review for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency; PDUFA Date Set for Feb. 17, 2022 ? ? Initiated ENERGIZE and ENERGIZE-T Phase 3 Studies in Thalassemia ? ? Agios to Host Investor Day on Nov. 17 to Share Pipeline Updates and Commercial Launch Strategy |
|
| November 3, 2021 |
Agreement, dated as of July 27, 2021, between the Registrant and Chris Bowden, M.D. July 27, 2021 Subject: Role change Dear Chris, Per our discussion, effective September1, 2021, you will begin your 6-week company paid sabbatical. |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2021 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2021 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| July 29, 2021 |
Exhibit 99.1 Agios Reports Business Highlights and Second Quarter 2021 Financial Results ? Completed Regulatory Submissions for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. and EU ? ? Presented Data from ACTIVATE and ACTIVATE-T Phase 3 Studies and Thalassemia Phase 2 Study at European Hematology Association Virtual Congress, Supporting Potential of PK Acti |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2021 (June 15, 2021) Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporatio |
|
| June 11, 2021 |
Exhibit 99.1 Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent ?- and ?-Thalassemia at the European Hematology Association Virtual Congress ? Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of ?1.0 g/dL in 16 of 20 (80%) Patients During Weeks 4-12 ? ? Mitapivat Safety Profile Consistent with Previously Published Studies ? |
|
| June 11, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 11, 2021 |
EX-99.2 3 d843751dex992.htm EX-99.2 Exhibit 99.2 Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress – Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 – – Agios t |
|
| May 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (a |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A (Amendment No. |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 29, 2021 |
Exhibit 99.1 Agios Reports Business Highlights and First Quarter 2021 Financial Results ? Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia Accepted for Presentation at EHA 2021 Virtual Congress ? ? Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficienc |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| April 8, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| April 6, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2021 (March 31, 2021) Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporati |
|
| April 6, 2021 |
UNAUDITED PRO FORMA FINANCIAL INFORMATION EX-99.1 2 d164250dex991.htm EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA FINANCIAL INFORMATION On March 31, 2021, Agios Pharmaceuticals, Inc. (“Agios”, the “Company” “we” or “us”) completed the previously announced proposed sale of the Company’s commercial, clinical and research-stage oncology portfolio (the “oncology business”) to Servier Pharmaceuticals, LLC (“Servier”), pursuant to the terms of the |
|
| April 5, 2021 |
EX-99.1 2 brhc10022784ex99-1.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with the other Reporting Person (as such term is defined in the Schedule 13D/A referred to below) on behalf of each of them of a statement on Schedule 13D (inc |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Agios Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 00847X104 (CUSIP Number) Sandra Leung, Esq. Bristol-Myers Squibb Company 430 East 29th Street, 14th Floor New York, New York 10016 (212) 546-3309 |
|
| April 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2021 (March 31, 2021) Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporati |
|
| April 2, 2021 |
Exhibit 10.1 SHARE REPURCHASE AGREEMENT This SHARE REPURCHASE AGREEMENT, dated as of March 31, 2021 (this ?Agreement?), is by and between by and between Bristol-Myers Squibb Company, a Delaware corporation (?BMS?), and Agios Pharmaceuticals, Inc., a Delaware corporation (the ?Purchaser?). RECITALS WHEREAS, BMS desires for the BMS Entities (as defined below) to sell shares of common stock, par valu |
|
| April 2, 2021 |
Exhibit 99.1 Agios Announces Closing of Oncology Business Sale to Servier Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio Agios Enters Into Agreement to Repurchase Approximately 10% of Its Outstanding Shares from Bristol-Myers Squibb for $344.5 Million CAMBRIDGE, Mass., April 1, 2021 ? Agios Pharmaceuticals, Inc. (NASDAQ: |
|
| March 25, 2021 |
Agios Shareholders Approve Sale of Oncology Business to Servier EX-99.1 Exhibit 99.1 Agios Shareholders Approve Sale of Oncology Business to Servier CAMBRIDGE, Mass., March 25, 2021 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that its shareholders voted to approve the previously disclosed sale of its commercial, clinical and research-stage oncology portfolio t |
|
| March 25, 2021 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 Agios Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36014 26-0662915 (State or other jurisdiction of incorporation) (Commiss |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 Agios Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36014 26-0662915 (State or other jurisdiction of incorporation) (Commiss |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 25, 2021 |
S-8 1 d149189ds8.htm S-8 As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-0662915 (State or Other Jurisdiction of Incorpo |
|
| February 25, 2021 |
EX-99.1 2 d123118dex991.htm EX-99.1 Exhibit 99.1 Agios Reports Fourth Quarter and Full Year 2020 Financial Results – Strong Commercial Execution for Second Full Year of TIBSOVO® with Fourth Quarter Net Revenue of $39.1M and $121.1M for Full Year 2020 – – Sale of Oncology Portfolio Expected to Close Around March 31 Subject to March 25 Shareholder Vote, Allowing Agios to Focus on Genetically Defined |
|
| February 25, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| February 25, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Entity State or other Jurisdiction of Incorporation or Organization Agios Securities Corporation Massachusetts Agios Limited Bermuda Agios International Sarl (GmbH) Switzerland Agios Netherlands B.V. The Netherlands Agios Germany GmbH Germany Agios Italy S.R.L. Italy Agios France SARL France |
|
| February 12, 2021 |
SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* AGIOS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 11, 2021 |
DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Agios Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 00847X104 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* Agios Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 29, 2021 |
EX-99.1 2 d112293dex991.htm EX-99.1 Exhibit 99.1 Agios Pharmaceuticals, Inc. Index to Consolidated Financial Statements Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets F-4 Consolidated Statements of Operations F-5 Consolidated Statements of Comprehensive Loss F-6 Consolidated Statements of Stockholders’ Equity F-7 Consolidated Statements of Cash Flows F-8 No |
|
| January 29, 2021 |
PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 26, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 26, 2021 |
EX-99.1 2 d25276dex991.htm EX-99.1 Exhibit 99.1 Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused – 37 Percent of Patients Treated with Mitapivat Achieved ³33% Reduction in Transfusion Burden Compared to Individual Historical Transfusion Burden Standardized to 24 Weeks (1-Sided p=0.0002) – – 22 Per |
|
| January 12, 2021 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| January 11, 2021 |
EX-99.1 2 d820976dex991.htm EX-99.1 Exhibit 99.1 Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation – Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. in Q2 2021 and in the EU in Mid-2021 – – Pivotal Trials for Mitap |
|
| January 11, 2021 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (C |
|
| January 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 23, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| December 22, 2020 |
EX-2.1 Exhibit 2.1 EXECUTED VERSION PURCHASE AND SALE AGREEMENT BY AND AMONG AGIOS PHARMACEUTICALS, INC., SERVIER PHARMACEUTICALS, LLC, AND, SOLELY FOR PURPOSES OF SECTION 11.15, SERVIER S.A.S. Dated as of December 20, 2020 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 5 Section 1.1 Definitions 5 Section 1.2 Other Defined Terms 26 ARTICLE II PURCHASE AND SALE; CLOSING 29 Section 2.1 Purchase and Sa |
|
| December 22, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2020 (December 20, 2020) Agios Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36014 26-0662915 (State or other jurisdiction of |
|
| December 22, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2020 (December 20, 2020) Agios Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36014 26-0662915 (State or other jurisdic |
|
| December 22, 2020 |
EX-2.1 2 d70467dex21.htm EX-2.1 Exhibit 2.1 EXECUTED VERSION PURCHASE AND SALE AGREEMENT BY AND AMONG AGIOS PHARMACEUTICALS, INC., SERVIER PHARMACEUTICALS, LLC, AND, SOLELY FOR PURPOSES OF SECTION 11.15, SERVIER S.A.S. Dated as of December 20, 2020 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 5 Section 1.1 Definitions 5 Section 1.2 Other Defined Terms 26 ARTICLE II PURCHASE AND SALE; CLOSING 29 Se |
|
| December 21, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| December 21, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2020 Agios Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36014 26-0662915 (State or other jurisdiction of incorporatio |
|
| December 21, 2020 |
EX-99.2 3 d93663dex992.htm EX-99.2 EMBRACING OUR PAST, REIMAGINING OUR FUTURE December 21, 2020 Exhibit 99.2 Important Information for Investors and Stockholders Additional Information and Where to Find It This communication relates to the proposed transaction involving the sale by Agios Pharmaceuticals, Inc. (“Agios”) of its oncology business to Servier Pharmaceuticals, LLC. In connection with th |
|
| December 21, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2020 Agios Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36014 26-0662915 (State or other jurisdiction of incorporation) (Comm |
|
| December 21, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| December 21, 2020 |
Investor Presentation, dated December 21, 2020 EMBRACING OUR PAST, REIMAGINING OUR FUTURE December 21, 2020 Exhibit 99.2 Important Information for Investors and Stockholders Additional Information and Where to Find It This communication relates to the proposed transaction involving the sale by Agios Pharmaceuticals, Inc. (“Agios”) of its oncology business to Servier Pharmaceuticals, LLC. In connection with the proposed transaction, Agios will |
|
| December 21, 2020 |
Press Release, dated December 21, 2020 Exhibit 99.1 Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties – Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building on its Scientific Expertise in Cellular Metabolism and PK Activation to Ac |
|
| December 21, 2020 |
EX-99.1 Exhibit 99.1 Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties – Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building on its Scientific Expertise in Cellular Metabolism and PK Activati |
|
| December 7, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 7, 2020 |
EX-99.1 2 d88252dex991.htm EX-99.1 Exhibit 99.1 Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease – Treatment with Mitapivat Induced Hemoglobin Increase of ³1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients, Decreased Markers of Hemolysis, Reduced 2,3-DPG and Increased ATP – – Safety Profile Generally Consistent with Previously P |
|
| December 1, 2020 |
EX-99.1 Exhibit 99.1 Agios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused – 40 Percent of Patients Treated with Mitapivat Achieved a Sustained Hemoglobin Increase of ³1.5 g/dL Compared to 0 Placebo Patients (p<0.0001) – – Safety Profile Consistent with Previously Reported Data – – Topline Da |
|
| December 1, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Agios Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00847X104 (CUSIP Number) October 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 5, 2020 |
EX-99.1 2 d74614dex991.htm EX-99.1 Exhibit 99.1 Agios Reports Business Highlights and Third Quarter 2020 Financial Results – Third Quarter TIBSOVO® Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO® Net U.S. Revenue Guidance to $113–115 Million – – Topline Data from the Mitapivat Phase 3 ACTIVATE Trial in Non-Transfusion Dependent PK Deficiency Expected by Year-End; Topline Phase 3 ACTIVA |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36014 AGIOS PHARMACEUTICALS, INC. |
|
| September 21, 2020 |
EX-99.1 Exhibit 99.1 Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients – Supplemental New Drug Application Planned for Submission in Q1 2021 – CAMBRIDGE, Mass., September 21, 2020 – Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat canc |
|
| September 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36014 26-0662915 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 8, 2020 |
EX-99.1 Exhibit 99.1 Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020 CAMBRIDGE, Mass., September 8, 2020 — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment o |
